Rituximab in systemic sclerosis-associated interstitial lung disease: A systematic review and meta-analysis.

In contrast, in cases of pneumonia and UTI, while rituximab showed a trend towards lower occurrence compared to cyclophosphamide, statistical significance was not achieved ( P = .11, P = .44, respectively).

also in 53,322 other papers

However, the three studies that assessed at 24 weeks and the two studies that assessed at 52 weeks, while showing a tendency to favor rituximab, did not reach statistical significance ( P = .18, P = .35, respectively).

also in 111,027 other papers

Analyses at 24 and 52 weeks also failed to reach statistical significance, although a trend toward greater mRSS reduction with rituximab was noted.

also in 6,035 other papers